Welcome to our dedicated page for Marizyme news (Ticker: MRZM), a resource for investors and traders seeking the latest updates and insights on Marizyme stock.
Marizyme, Inc. (MRZM) delivers innovative biotechnology solutions targeting critical needs in acute care, most notably through its FDA-cleared DuraGraft™ system for cardiac surgeries. This news hub provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and commercial developments.
Our curated collection features official press releases detailing product innovations, financial performance reports, and strategic partnership announcements. Key focus areas include CABG surgery advancements, vascular conduit research, and therapeutic pipeline updates. All content is vetted for accuracy and timeliness.
Regular updates cover:
• FDA regulatory progress
• Clinical trial results
• Financial disclosures
• Surgical community adoption metrics
Bookmark this page for streamlined access to MRZM's latest developments in cardiac care innovation and corporate growth initiatives. Verify time-sensitive information directly through SEC filings and official company communications.
Marizyme (OTCQB: MRZM) announced that the USPTO has granted a Notice of Allowance for its patent application related to DuraGraft, a solution enhancing organ and tissue preservation during surgeries. This patent, covering a stable solution kit, is significant for the company's flagship product, currently approved in Europe and seeking FDA approval in the U.S. CEO David Barthel emphasized that the allowance strengthens their patent estate and protects commercial opportunities in the U.S., reflecting a crucial milestone for Marizyme.
Marizyme Inc. (OTCQB:MRZM) has successfully closed its acquisition of My Health Logic Inc., a subsidiary of Health Logic Interactive Inc. This acquisition enhances Marizyme's product pipeline with My Health Logic's lab-on-chip technology and MATLOC 1 device, aimed at improving chronic kidney disease (CKD) diagnostics. Concurrently, a private placement of $6 million was completed to support business development. The company is also positioned for an anticipated public offering and Nasdaq uplisting in 2022.
Marizyme Inc. (MRZM) announced the results of the GOAL Study at the 7th Annual International Coronary Congress. Conducted by Dr. Bernhard Winkler, this study evaluated DuraGraft® Vascular Conduit Solution versus standard care during CABG surgeries. Results showed significant reductions in perioperative high-sensitivity Troponin-I levels in patients using DuraGraft, suggesting enhanced myocardial protection. These findings validate earlier research and highlight DuraGraft's potential in cardiac surgery, paving the way for more extensive investigations into its long-term benefits.
Marizyme Inc. (MRZM) has received notice for the allowance of foundational patent applications in key markets for its core technologies. This includes patent protections for its flagship product, DuraGraft®, in Brazil, China, and Malaysia, enhancing its commercial potential. DuraGraft® is designed to improve outcomes in vascular surgeries by preserving grafts during procedures. Additionally, a patent related to its Krillase enzyme technology has been allowed in Europe, expanding its therapeutic applications. The company has partnered with Dentons US LLP to manage its global patent portfolio.
FAQ
What is the current stock price of Marizyme (MRZM)?
What is the market cap of Marizyme (MRZM)?
